Why Moderna Stock Soared to a New All-Time High Today

What happened

Shares of Moderna (NASDAQ: MRNA) climbed 16% on Friday, following reports that the biotech company is negotiating an advanced purchase deal for its experimental COVID-19 vaccine with the European Union.

Moderna's stock, which closed at a record high of $94.85, is now up a stunning 385% so far in 2020.

So what 

The EU is attempting to line up deals with several coronavirus vaccine makers, according to Reuters. Among these companies are Johnson & Johnson (NYSE: JNJ), Sanofi (NASDAQ: SNY), BioNTech (NASDAQ: BNTX), and Moderna. "We are in talks with several companies on possible COVID-19 vaccines," an EU spokesperson told Reuters on Friday. 

A person is pointing to an upwardly sloping chart.

Moderna's stock has delivered incredible returns to investors. Image source: Getty Images.

The EU's negotiations are reportedly in more advanced stages with Johnson & Johnson and Sanofi, which could potentially supply its 27 member states with as many as 200 million and 300 million vaccine doses, respectively. Talks with Moderna were said to be ongoing.

Now what 

Governments around the world are racing to lock in deals that could supply their citizens with COVID-19 vaccines, should they prove safe and effective. With COVID-19 case counts rising at an alarming rate in many countries, competition among nations for these potentially life-saving drugs will likely intensify in the months ahead.

It's also unsurprising that the EU would want to strike a deal with Moderna. A recent analysis published in The New England Journal of Medicine showed that Moderna's experimental vaccine helped to produce neutralizing antibodies -- which scientists say could defend against coronavirus infections -- in 100% of its phase 1 study participants. Though more testing is needed, the results are considered notable progress toward the development of a potential COVID-19 vaccine.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 2, 2020


Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More